740 Biomarkers diverging between tumor mutation burden and microsatellite instability

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A786-A787
Author(s):  
Jason Ding ◽  
Nihir Patel

BackgroundDNA repair is a critical process to maintain DNA integrity. It is conducted by distinct pathways of genes, many of whose alterations are thought to result in genomic instability and hypermutability, ultimately contributing to tumorigenesis. Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) are considered as efficacy biomarkers for immunotherapy.1 2 However, there has been little characterization of the association between DNA repair genes and TMB/MSI in cancer. This study aims to further understand DNA repair genes and evaluate the contribution of their alteration to TMB and MSI.MethodsWe systematically analyzed 282 DNA repair genes involved in 20 DNA repair pathways. These genes were evaluated for mutations based on 274 sequenced colorectal tumor samples from the TCGA database. The functional impacts of these mutations were analyzed, and only damaging mutations were used for the subsequent analysis. The most frequently mutated genes were identified. The association between the damaging mutations and TMB/MSI status was calculated for each gene, and the significant genes were subject to further pathway enrichment analysis. We also compared the gene expression between TMB high and low as well as between MSI-H and MSI-L/MSS for each gene based on their RNAseq data. The potential associations with TMB/MSI high phenotypes were evaluated.Results94 genes were identified to be significantly mutated in TMB high, including all of the 26 genes that were significant in MSI-H . The genes are enriched in multiple pathways, including Fanconi anemia, Base excision repair, and Mismatch repair. At the expression level, 28 genes are significantly downregulated in TMB high samples, while 35 genes in MSI-H, suggesting that the inactivation of these genes might be mediated by epigenetic abnormalities (figure 1). 10 genes, including POLE, were identified that are significantly mutated in TMB high samples as compared to MSI-H samples (table 1). Loss of function of these genes may result in an ultra-mutated phenotype. Contradicting the notion that POLE mutation is predominantly associated with MSS tumors and are mutually exclusive with the complete loss of MMR,4–6 we found about half of POLE-mutant samples (8/16) were MSI high, five of which had MMR mutations (figure 2).Abstract 740 Figure 1Venn diagram of significant genes associated with MSI-H and TMB-high, identified using expression changes and loss of function mutations.Abstract 740 Table 1Genes significantly mutated in TMB-high compared to MSI-H.Abstract 740 Figure 2MLH1 expressed significantly lower in MSI-H samplesConclusionsThe study investigated the association of DNA repair genes with TMB and MSI. We compared genes significantly altered in TMB high and MSI-H samples and identified genes pointing to a potential mechanism that induces ultra-mutation in a subset of cancer patients with intact MMR, which can serve as potential biomarkers for immunotherapy efficacy linked with high TMB.ReferencesChan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30(1):44–56.Chang L, Chang M, Chang HM, Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem Mol Morphol 2018;26(2):e15–e21.Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–337.Albertson TM, Ogawa M, Bugni JM, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 2009;106:17101-17104.Church DN, Briggs SE, Palles C, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013;22:2820–2828.Valle L, Hernandez-Illan E, Bellido F, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 2014;23:3506–3512.

2020 ◽  
Author(s):  
Unbeom Shin ◽  
Khriezhanuo Nakhro ◽  
Chang-Kyu Oh ◽  
Blake Carrington ◽  
Hayne Song ◽  
...  

ABSTRACTA systematic knowledge of the roles of DNA repair genes at the level of the organism has been limited due to the lack of appropriate experimental techniques. Here, we generated zebrafish loss-of-function mutants for 32 DNA repair and replication genes through multiplexed CRISPR/Cas9-mediated mutagenesis. High-throughput phenotypic characterization of our mutant collection revealed that three genes (atad5a, ddb1, pcna) are essential for proper embryonic development and hematopoiesis; seven genes (apex1, atrip, ino80, mre11a, shfm1, telo2, wrn) are required for growth and development during juvenile stage and six genes (blm, brca2, fanci, rad51, rad54l, rtel1) play critical roles in sex development. Furthermore, mutation in six genes (atad5a, brca2, polk, rad51, shfm1, xrcc1) displayed hypersensitivity to DNA damage agents. Further characterization of atad5a−/− mutants demonstrate that Atad5a is required for normal brain development and hematopoiesis. Our zebrafish mutant collection provides a unique resource for understanding of the roles of DNA repair genes at the organismal level.


2020 ◽  
Vol 8 (1) ◽  
pp. e000319 ◽  
Author(s):  
Matthew Kyle Labriola ◽  
Jason Zhu ◽  
Rajan Gupta ◽  
Shannon McCall ◽  
Jennifer Jackson ◽  
...  

BackgroundImmune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) status demonstrating little predictive utility in mRCC. While predictive of ICI response in other tumor types, the utility of tumor mutation burden (TMB) in mRCC is unclear. Here, we assess TMB, loss of antigen presentation genes and PD-L1 status correlated with outcomes to ICI treatment in mRCC.MethodsTumor samples from 34 patients with mRCC treated with ICI therapy at Duke Cancer Institute were retrospectively evaluated using Personal Genome Diagnostics elio tissue complete (RUO version), a tumor genomic profiling assay for somatic variants, TMB, microsatellite status and genomic status of antigen presentation genes. Tumor samples were also analyzed with the Dako 28-8 PD-L1 immunohistochemistry assay. Deidentified clinical information was extracted from the medical record, and tumor response was evaluated based on the Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1 criteria.ResultsPatients were stratified by overall response following ICI therapy and designated as progressive disease (PD; n=18) or disease control groups (DC; n=16). TMB scores ranged from 0.36 to 12.24 mutations/Mb (mean 2.83 mutations/Mb) with no significant difference between the PD and DC groups (3.01 vs 2.63 mutations/Mb, respectively; p=0.7682). Interestingly, 33% of PD patients displayed loss of heterozygosity of major histocompatibility complex class I genes (LOH-MHC) vs 6% of DC patients. Nine of 34 samples were PD-L1-positive (4 in the PD group; 5 in the DC group), suggesting no correlation between PD-L1 expression and response to ICI therapy. Notably, the DC group displayed an enrichment of mutations in DNA repair genes (p=0.04), with 68.8% exhibiting at least one mutated homologous recombination repair (HRR)-related gene compared with only 38.9% of the PD group (p=0.03).ConclusionsOverall, neither TMB nor PD-L1 correlated with ICI response and TMB was not significantly associated with PD-L1 expression. The higher incidence of LOH-MHC in PD group suggests that loss of antigen presentation may restrict response to ICIs. Separately, enrichment of HRR gene mutations in the DC group suggests potential utility in predicting ICI response and a potential therapeutic target, warranting future studies.


PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0193823
Author(s):  
Changshin Kim ◽  
Jinmo Yang ◽  
Su-Hyun Jeong ◽  
Hayoung Kim ◽  
Geun-hee Park ◽  
...  

Biomedicines ◽  
2020 ◽  
Vol 8 (7) ◽  
pp. 215
Author(s):  
Matthias Schaks ◽  
Kristina Allgoewer ◽  
Nina Nelson ◽  
Patrick Ehm ◽  
Asmus Heumann ◽  
...  

Colorectal cancer (CRC) is a heterogeneous disease that results from the accumulation of mutations in colonic mucosa cells. A subclass of CRC is characterized by microsatellite instability, which is thought to occur mainly through inactivation of the DNA mismatch repair genes MLH1 and MSH2. The inositol 5-phosphatase SHIP1 is expressed predominantly in hematopoietic cells. In this study, the expression of SHIP1 in carcinomas and its putative correlation with clinicopathologic parameters, expression of DNA repair genes and microsatellite instability was investigated. By analyzing a multi-tumor tissue microarray, expression of SHIP1 was detected in 48 out of 72 cancer entities analyzed. The expression of SHIP1 protein of 145 kDa was confirmed by Western blot analysis in 7 out of 14 carcinoma cell lines. Analysis of a large colorectal cancer tissue microarray with 1009 specimens revealed SHIP1 expression in 62% of the samples analyzed. SHIP1 expression was inversely correlated with lymph node metastasis, vascular invasion and tumor grade, and it was positively associated with left-sided tumor localization. Interestingly, a strong relationship between the expression of SHIP1 and nuclear and membranous beta-catenin and the DNA repair genes MLH1 and MSH2 was observed.


2003 ◽  
Vol 111 (15) ◽  
pp. 1843-1850 ◽  
Author(s):  
William W Au ◽  
Salama A Salama ◽  
Carlos H Sierra-Torres

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 276-276
Author(s):  
Terry J Gaymes ◽  
Rajani Chelliah ◽  
Austin G Kulasekararaj ◽  
Azim M Mohamedali ◽  
Sydney Shall ◽  
...  

Abstract Abstract 276 In both myelodysplatic syndrome (MDS) and acute myeloid leukaemia (AML), relapse from standard chemotherapeutic intervention is common with only 20–30% enjoying long-term disease-free survival. Allogeneic stem cell transplantation still remains the only curative treatment in MDS/AML, but only in 15–20% of patients. Older patients (>70 years) that constitute the majority of MDS/AML patients are often resistant to chemotherapy, achieve short lived remission and are not candidates for stem cell transplantation. Given the high number of patients refractory to conventional therapy and the relatively high rate of therapy relapse, efforts have been made in the search for alternative treatment strategies. Inhibition of Poly ADP ribose polymerase (PARP) activity can selectively target cancer cells through exploitation of inherent DNA repair defects. Significant single agent anti-tumour responses coupled with a wide therapeutic index have been influential in moving PARP inhibitors (PARPi) to the clinical arena. MDS/AML is characterized by chromosomal instability (CI) manifesting as deletions, translocations and chromosome losses. Single nucleotide polymorphism arrays (SNPA) karyotyping show that loss of heterozygosity (LOH) and uniparental disomy (UPD) are common in MDS/AML and thus it has been suggested that the underlying cause of this CI is a defect in double strand DNA repair. We have previously shown that 15% of AML and MDS primary patient cells and cell lines are sensitive to PARPi through exploitation of homologous recombination DNA repair defects. To explicate still further the mechanisms that support PARPi sensitivity in MDS/AML we tested for microsatellite instability (MSI) in primary high risk MDS and primary AML for the presence of frameshift mutations in specific DNA repair genes. 13 of 63 (21%) high risk MDS patients possessed MSI (9 MSI-low and 4 MSI-high). Significantly, all 13 MSI positive patients possessed chromosomal abnormalities, both gross and cryptic UPD determined by SNPA, whilst 12 patients (19%) found to be have normal cytogenetics and lacking UPD failed to demonstrate MSI. Moreover, 3 patients with MSI-high and 1 patient with MSI-low possessed a mono-allelic 1bp deletion in the CTiP exon coding microsatellite. 1bp deletion within the coding exon of CTiP would result in an abbreviated gene CTiP transcript in these patients. From a panel of 18 primary AML samples, 5 primary AML demonstrated sensitivity to the PARPi, BMN673 (100nM). Immunocytochemical staining also showed that PARPi sensitive AML cells demonstrated severely reduced rad51 and increased phospho-γH2AX foci formation compared to PARPi insensitive AML cells. This confirmed that BMN673 targeted HR deficiencies in AML PARPi sensitive cells. Strikingly, 2 of the 5 PARPi responders exhibited MSI, with 1 patient displaying a bi-allelic 1bp deletion in MRe11 and 1 patient exhibiting a mono-allelic 1bp deletion in CTiP. MSI was not observed in the 13 PARPi insensitive AML patients. Western blotting analysis identified the loss of mismatch repair proteins MLH-1 and MSH-2 respectively, in the 2 MSI positive primary AML underlying the MSI observed in the AML patients cells. Moreover, Western blotting analysis also revealed aberrant expression of Mre11 and CTiP in these patients. Finally, to confirm the relative contribution of mutant MRe11 and CTiP to PARPi sensitivity, an expression construct of MRe11 missing exons 5 to 7 (δ5–7MRe11) was transfected into the MSI negative and PARPi insensitive cell line, U937. Cytotoxicity assays and immunocytochemical staining revealed that U937 + δ5–7MRe11 demonstrated significant sensitivity to PARPi with concomitant HR DNA repair defects compared to U937 + vector control. Similarly, Si-RNA knockdown of CTiP in U937 also conferred hypersensitivity to PARPi as a result of an abrogation of functional HR DNA repair. In conclusion, we make the unique observation that MSI dependent mutations in genes that are essential for DNA repair signalling confer PARPi sensitivity in myeloid malignancy. Identification of a cohort of MDS/AML patients with MSI would signify a major development in the identification of candidates for PARPi therapy. Disclosures: No relevant conflicts of interest to declare.


1983 ◽  
Vol 7 (2) ◽  
pp. 85-92 ◽  
Author(s):  
David Schild ◽  
Boyana Konforti ◽  
Carl Perez ◽  
Warren Gish ◽  
Robert Mortimer

Sign in / Sign up

Export Citation Format

Share Document